Peptide Half-Life Explained: Plasma Half-Life vs. Shelf Life
Every peptide page lists a half-life — and it is one of the most misread numbers in the whole field. Here is what plasma half-life actually measures, why it is completely separate from how long a vial lasts, and how conflating the two produces the contradictory answers you find online.
The 60-second version
A peptide's half-life almost always means its plasma (elimination) half-life — the time for its concentration in your bloodstream to fall by half. It is a pharmacokinetic property that determines dosing frequency: semaglutide's roughly one-week half-life is why it is dosed weekly. It says nothing about how long the peptide lasts in the vial. Shelf life — vial stability — is a separate chemical-stability property, measured in months or years for a dry peptide and weeks once reconstituted. A peptide can have a 7-day plasma half-life and a 2-year shelf life; the numbers are not related. Conflating them is one of the main reasons online answers about how long peptides last contradict each other.
Key takeaways
- The half-life listed on a peptide page is plasma (elimination) half-life — the time for the compound's blood concentration to fall by half.
- Plasma half-life is a pharmacokinetic property that largely determines dosing frequency — semaglutide's ~1-week half-life is why it is dosed weekly.
- A compound reaches steady, predictable blood levels after roughly four to five half-lives of consistent dosing.
- Duration of action — how long the effect lasts — is a third, separate timescale that does not always match plasma half-life.
- Shelf life is the chemical stability of the product in its container — months to years lyophilized, weeks once reconstituted.
- Plasma half-life is fixed by molecular structure and physiology; shelf life is something storage conditions can influence.
- Conflating plasma half-life with shelf life is a major reason online answers about how long peptides last contradict each other.
Two completely different clocks
Open any peptide page — on this site or anywhere else — and you will find a line for "half-life." It is one of the most consulted numbers in the field, and one of the most misread. People see it and reasonably ask: is that how long the peptide lasts? In my body? In the vial?
The answer is that "half-life," as listed, almost always means one specific thing — plasma half-life — and it tells you nothing about how long the product lasts in storage. Those are two separate clocks measuring two unrelated processes. Confusing them is behind a surprising amount of the contradictory advice you find when you go looking.
Plasma half-life: what it actually measures
Plasma half-life — more precisely the elimination half-life — is the time it takes for the concentration of a compound in your bloodstream to fall by half, after it has been absorbed and distributed.
It is a pharmacokinetic property: a description of what your body does to the drug. A short plasma half-life means the body clears the compound quickly; a long one means it lingers. Native GLP-1, the natural hormone, has a plasma half-life of roughly one to two minutes, because an enzyme called DPP-4 degrades it almost immediately. Semaglutide — engineered specifically to resist that degradation and to bind to albumin in the blood — has a plasma half-life of about a week. Same receptor target; a thousand-fold difference in how long the molecule survives in circulation.
The number is measured the same way for every drug: dose it, draw blood at intervals, plot how the concentration falls, and calculate the time for each successive halving.
Why plasma half-life sets the dosing schedule
Plasma half-life is the single most useful thing the number tells you, because it largely determines how often a compound is dosed.
Semaglutide's ~1-week half-life is the entire reason it is a once-weekly injection — a week after a dose, roughly half the drug is still present, so weekly dosing keeps blood levels in a usefully steady band. Tirzepatide, with a half-life around five days, is also weekly. Liraglutide, at roughly 13 hours, has to be daily. Native peptides with half-lives measured in minutes cannot be practical drugs at all without modification — which is precisely why so much peptide engineering is aimed at extending half-life.
A rule of thumb: a compound reaches steady state — stable, predictable blood levels — after roughly four to five half-lives of consistent dosing. For semaglutide that is four to five weeks, which is why dose changes take about a month to fully express themselves. None of this has anything to do with the vial.
Duration of action: a third number worth knowing
Briefly, because it adds a third thing people conflate: duration of action — how long a drug's effect lasts — is not always the same as plasma half-life. A drug can bind its receptor tightly and keep producing an effect after most of it has cleared, or trigger downstream changes that outlast the molecule. So there are really three distinct timescales: how long the molecule stays in your blood (plasma half-life), how long it keeps working (duration of action), and how long the product is good in storage (shelf life). The peptide-page number is the first of those.
Shelf life: the vial clock
Shelf life is a completely different kind of property. It describes the chemical stability of the product in its container — how long it remains potent and safe before degradation reactions accumulate enough to matter.
Shelf life is governed by storage chemistry: hydrolysis, oxidation, aggregation, microbial growth, temperature, light, and — above all — whether the peptide is dry or in solution. A lyophilized (freeze-dried) peptide can have a shelf life of two years or more frozen, because almost no degradation chemistry can run without water. The same peptide, once reconstituted, has a shelf life measured in weeks. We cover that in detail in our reconstituted-peptide storage guide.
The key point: shelf life is something you can influence — by how you store the vial — and plasma half-life is not. Plasma half-life is fixed by the molecule's structure and your physiology. You cannot store a peptide in a way that changes its half-life in your bloodstream.
Why the confusion happens
Three things drive the mix-up. First, language: "half-life" sounds like a general expiry term, and "how long does it last" is a genuinely ambiguous question — last in your body, or last in the vial? Second, the word "half-life" does have a legitimate use in chemical decay — radioactive half-life is the classic case — so it is reasonable to imagine a peptide "decaying" on a half-life in the fridge. In practice, peptide storage stability is described with shelf-life dating and degradation rates rather than a single "half-life," so the term you see on a peptide page is the pharmacokinetic one. Third, the two numbers can look similar — semaglutide's plasma half-life is about a week, and a reconstituted peptide's fridge life is a few weeks — which makes it easy to assume they are the same kind of measurement. They are not.
A worked example
Take semaglutide. Its plasma half-life is about seven days — that is why it is injected weekly, and why it takes a month or so of consistent dosing to reach steady state. Its shelf life depends entirely on the product: an unopened pen is dated by the manufacturer for storage under refrigeration until its printed expiry — often a year or more out — and, once in use, is rated for a defined further window (for Ozempic, 56 days). Those are three different numbers: about 7 days, "until printed expiry," and 56 days. Only the first is a half-life. A patient who reads "half-life: 7 days" and concludes the pen expires a week after opening has merged two clocks that have nothing to do with each other.
The honest read
When you see "half-life" on a peptide page, read it as: how long the compound persists in the bloodstream, which is why it is dosed on the schedule it is. It is a fact about pharmacology, not about storage. If your question is how long the vial is good for, that is shelf life — a separate property, covered in our storage guide. Keeping the two clocks separate is one of the simplest ways to stop getting contradictory answers.
Frequently asked questions
Does the half-life tell me how long my vial will last?
No. That figure is plasma half-life — how long the compound lasts in your bloodstream. How long the vial stays good is shelf life, a separate chemical-stability property covered in our storage guide.
Why does semaglutide have a one-week half-life when natural GLP-1 lasts minutes?
Semaglutide is engineered for it. Native GLP-1 is degraded by the enzyme DPP-4 within minutes; semaglutide resists that degradation and binds tightly to albumin in the blood, which keeps it in circulation roughly a thousand times longer.
What does half-life have to do with dosing frequency?
Almost everything. A long half-life means the drug is still present when the next dose is due, so it can be dosed infrequently. It also takes about four to five half-lives of consistent dosing to reach stable, steady-state blood levels.
Is duration of effect the same as half-life?
Not always. A drug can keep producing an effect after most of it has cleared — through tight receptor binding or downstream changes that outlast the molecule. Duration of action and plasma half-life are related but distinct.
Can I change a peptide's half-life by how I store it?
No. Plasma half-life is fixed by the molecule's structure and your physiology. Storage conditions affect shelf life — how long the product stays stable in the vial — not half-life.
Why do dose changes take weeks to fully show their effect?
Because it takes roughly four to five half-lives of consistent dosing to reach a new steady state. For a weekly drug like semaglutide, that is about four to five weeks after a dose change.
References
- Lau J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. https://pubmed.ncbi.nlm.nih.gov/26308095/
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. https://pubmed.ncbi.nlm.nih.gov/31031702/
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. https://pubmed.ncbi.nlm.nih.gov/20143256/
We update articles as new trials publish and the evidence base evolves. Last reviewed: May 2026.